These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25841601)

  • 41. What's new in hepatitis C virus infections in children?
    Pawlowska M; Domagalski K; Pniewska A; Smok B; Halota W; Tretyn A
    World J Gastroenterol; 2015 Oct; 21(38):10783-9. PubMed ID: 26478670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.
    Shah H; Bilodeau M; Burak KW; Cooper C; Klein M; Ramji A; Smyth D; Feld JJ;
    CMAJ; 2018 Jun; 190(22):E677-E687. PubMed ID: 29866893
    [No Abstract]   [Full Text] [Related]  

  • 43. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy.
    Kushner T; Reau N
    J Hepatol; 2021 Mar; 74(3):734-741. PubMed ID: 33248169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming the roadblocks in hepatitis C virus infection.
    Baumert TF; Zeuzem S
    J Hepatol; 2014 Nov; 61(1 Suppl):S1-2. PubMed ID: 25443338
    [No Abstract]   [Full Text] [Related]  

  • 45. Update on chronic hepatitis C.
    Wong W; Terrault N
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):507-20. PubMed ID: 15952092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic Hepatitis C Virus Infection and Depression.
    Adinolfi LE; Nevola R; Rinaldi L; Romano C; Giordano M
    Clin Liver Dis; 2017 Aug; 21(3):517-534. PubMed ID: 28689590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue.
    Razavi H; Bruggmann P; Wedemeyer H; Dore G
    J Viral Hepat; 2014 Dec; 21(12):e169-70. PubMed ID: 25262767
    [No Abstract]   [Full Text] [Related]  

  • 48. Alcoholic hepatitis and concomitant hepatitis C virus infection.
    Shoreibah M; Anand BS; Singal AK
    World J Gastroenterol; 2014 Sep; 20(34):11929-34. PubMed ID: 25232227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expert opinion on managing chronic HCV in patients with cardiovascular disease.
    Vassalle C; Petta S; Pepe A; Craxi A; Bondin M; Cacoub P
    Antivir Ther; 2018; 23(Suppl 2):35-46. PubMed ID: 30451152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue.
    Hickman M; Martin N; Vickerman P; Hutchinson S
    J Viral Hepat; 2014 Dec; 21(12):e167-8. PubMed ID: 25262826
    [No Abstract]   [Full Text] [Related]  

  • 51. Epidemiology of Hepatitis C Virus: A Battle on New Frontiers.
    Shire NJ; Sherman KE
    Gastroenterol Clin North Am; 2015 Dec; 44(4):699-716. PubMed ID: 26600215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C in the United States.
    Holmberg SD; Spradling PR; Moorman AC; Denniston MM
    N Engl J Med; 2013 May; 368(20):1859-61. PubMed ID: 23675657
    [No Abstract]   [Full Text] [Related]  

  • 53. Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.
    Forton D; Weissenborn K; Bondin M; Cacoub P
    Antivir Ther; 2018; 23(Suppl 2):47-55. PubMed ID: 30451150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Risk factors of HBV/HCV infection-related hepatic steatosis and relationship with antiviral therapy].
    Zhang Q; Wang J
    Zhonghua Nei Ke Za Zhi; 2014 Jul; 53(7):513-6. PubMed ID: 25264003
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment for hepatitis C virus infection in India: Promising times.
    Abraham P
    Indian J Med Microbiol; 2016; 34(3):273-4. PubMed ID: 27514946
    [No Abstract]   [Full Text] [Related]  

  • 56. PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy.
    Kondili LA; Vella S;
    Dig Liver Dis; 2015 Sep; 47(9):741-3. PubMed ID: 26138800
    [No Abstract]   [Full Text] [Related]  

  • 57. [Not Available].
    Bruggmann P
    Praxis (Bern 1994); 2016 Jul; 105(15):885-9. PubMed ID: 27463274
    [No Abstract]   [Full Text] [Related]  

  • 58. [Epidemiology of hepatitis C and vaccine perspectives].
    Nau JY
    Rev Med Suisse; 2016 Jan; 12(503):234-5. PubMed ID: 26939196
    [No Abstract]   [Full Text] [Related]  

  • 59. High Prevalence of New-Onset or Worsening Hepatitis C Virus-Related Musculoskeletal Symptoms After Beginning Direct-Acting Antiviral Therapy: A Challenging Novel Observation.
    Haroon M; Anis K; Khan Z; Nawaz N
    Arthritis Rheumatol; 2021 Feb; 73(2):355-356. PubMed ID: 32840965
    [No Abstract]   [Full Text] [Related]  

  • 60. Chronic hepatitis C: the virus, its discovery and the natural history of the disease.
    Booth JC
    J Viral Hepat; 1998 Jul; 5(4):213-22. PubMed ID: 9751007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.